Evidence map›Paper›PMID 27393121›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2016

New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system).

N E Carlozzi, N R Downing, M K McCormack, S G Schilling, J S Perlmutter, E A Hahn, J S Lai, S Frank, K A Quaid, J S Paulsen and 4 more

Open access · greenAbstract read
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Primary Palliative Care in Huntington's Disease.Movement disorders clinical practice · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Assessing meaning & purpose in life: development and validation of an item bank and short forms for the NIH PROMISQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018
    Article
  13. Understanding the need for assistance with survey completion in people with Huntington disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2018
    Article
  14. Factors Associated With End-of-Life Planning in Huntington Disease.The American journal of hospice & palliative care · 2018
    Article
  15. Article
  16. Article
  17. Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington's Disease.The Journal of neuropsychiatry and clinical neurosciences · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

N E CarlozziDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA. carlozzi@med.umich.edu.ORCID 0000-0003-0439-9429
N R DowningCollege of Nursing, The University of Iowa, Iowa City, IA, USA.
M K McCormackDepartment of Pathology, Rowan University, Piscataway, NJ, USA.
S G SchillingInstitute for Social Research, University of Michigan, Ann Arbor, MI, USA.
J S PerlmutterDepartments of Neurology, Radiology, and Anatomy and Neurobiology, Washington University School of Medicine, St. Louis, MO, USA.
E A HahnDepartment of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
J S LaiCenter on Outcomes, Research and Education, Evanston Northwestern Healthcare, Northwestern University, Evanston, IL, USA.
S FrankBeth Israel Deaconess Medical Center, Boston, MA, USA.
K A QuaidDepartment of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA.
J S PaulsenDepartment of Psychiatry, Carver College of Medicine, The University of Iowa, Iowa City, IA, USA.
D CellaDepartment of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
S M GoodnightDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA.
J A MinerDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, MI, USA.
M A NanceHennepin County Medical Center, Minneapolis, MN, USA.
University of Michigan · USNorthwestern University · USUniversity of Iowa · USBeth Israel Deaconess Medical Center · USHennepin County Medical Center · USIndiana University – Purdue University Indianapolis · USRowan University · USWashington University in St. Louis · US

Funding

Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
NEUROBIOLOGICAL PREDICTORS OF HUNTINGTON'S DISEASER01NS040068 · NINDS · UNIVERSITY OF IOWA · PI PAULSEN, JANE S · 2001 to 2013
$48.5M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Validation of the HD-HRQOL (Huntington disease quality of life measure)R01NS077946 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARLOZZI, NOELLE E. · 2012 to 2016
$3.2M
NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR001108NINDS NIH HHS R01 NS040068NINDS NIH HHS R01 NS077946
6 · The paper itself

Abstract

purposeHuntington disease (HD) is an incurable terminal disease. Thus, end of life (EOL) concerns are common in these individuals. A quantitative measure of EOL concerns in HD would enable a better understanding of how these concerns impact health-related quality of life. Therefore, we developed new measures of EOL for use in HD.

methodsAn EOL item pool of 45 items was field tested in 507 individuals with prodromal or manifest HD. Exploratory and confirmatory factor analyses (EFA and CFA, respectively) were conducted to establish unidimensional item pools. Item response theory (IRT) and differential item functioning analyses were applied to the identified unidimensional item pools to select the final items.

resultsEFA and CFA supported two separate unidimensional sets of items: Concern with Death and Dying (16 items), and Meaning and Purpose (14 items). IRT and DIF supported the retention of 12 Concern with Death and Dying items and 4 Meaning and Purpose items. IRT data supported the development of both a computer adaptive test (CAT) and a 6-item, static short form for Concern with Death and Dying.

conclusionThe HDQLIFE Concern with Death and Dying CAT and corresponding 6-item short form, and the 4-item calibrated HDQLIFE Meaning and Purpose scale demonstrate excellent psychometric properties. These new measures have the potential to provide clinically meaningful information about end-of-life preferences and concerns to clinicians and researchers working with individuals with HD. In addition, these measures may also be relevant and useful for other terminal conditions.

Indexed as

Sickness Impact ProfileAdolescentAdultAgedAged, 80 and overDeathFemaleHumansHuntington DiseaseMaleMiddle AgedPatient Reported Outcome MeasuresSurveys and QuestionnairesTerminal CareYoung AdultEnd of lifeHDQLIFEHealth-related quality of lifeHuntington diseaseNeuro-QoLPatient-reported outcome (PRO)PROMIS

Identifiers

PMID27393121
PMCPMC5011453
OpenAlexW2463571448

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.